Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian S Dobs

Showing results (11-20 of 120) with videos related to

Pageof 12
Sort By:
The Journal of Clinical Endocrinology and Metabolism|August 10, 2020
Opioids and the Hypothalamic-Pituitary-Gonadal (HPG) AxisLeen Wehbeh, Adrian S Dobs
Touchreviews in Endocrinology|January 25, 2023
Testosterone Replacement Therapy: A Narrative Review with a Focus on New Oral FormulationsSalman Z Bhat, Adrian S Dobs
Future Oncology (London, England)|October 27, 2009
Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexiaMihail F Zilbermint, Adrian S Dobs
Journal of Clinical Pharmacology|November 5, 2002
Endocrine effects of marijuanaTodd T Brown, Adrian S Dobs
Current Opinion in Endocrinology, Diabetes, and Obesity|February 21, 2013
The effect of androgens on lipidsAnne K Monroe, Adrian S Dobs
The Journal of Clinical Endocrinology and Metabolism|February 11, 2026
Will Selective Androgen Receptor Modulators Ever Reach The Clinic?Jenny Pena Dias, Adrian S Dobs
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|September 14, 2002
Streamlining the clinical research enterpriseBernard A Schwetz, Adrian S Dobs
Drugs|August 8, 2012
Topical testosterone supplementation for the treatment of male hypogonadismKatrina A Abadilla, Adrian S Dobs
Current Opinion in Endocrinology, Diabetes, and Obesity|October 18, 2007
Androgen deficiency, diabetes, and the metabolic syndrome in menRita R Kalyani, Adrian S Dobs
Expert Opinion on Pharmacotherapy|August 10, 2005
Nebido: a long-acting injectable testosterone for the treatment of male hypogonadismLindsey Harle, Shehzad Basaria, Adrian S Dobs
Pageof 12

Showing results (11-20 of 120) with videos related to

Sort By:
Pageof 12
The Journal of Clinical Endocrinology and Metabolism|August 10, 2020
Opioids and the Hypothalamic-Pituitary-Gonadal (HPG) AxisLeen Wehbeh, Adrian S Dobs
Touchreviews in Endocrinology|January 25, 2023
Testosterone Replacement Therapy: A Narrative Review with a Focus on New Oral FormulationsSalman Z Bhat, Adrian S Dobs
Future Oncology (London, England)|October 27, 2009
Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexiaMihail F Zilbermint, Adrian S Dobs
Journal of Clinical Pharmacology|November 5, 2002
Endocrine effects of marijuanaTodd T Brown, Adrian S Dobs
Current Opinion in Endocrinology, Diabetes, and Obesity|February 21, 2013
The effect of androgens on lipidsAnne K Monroe, Adrian S Dobs
The Journal of Clinical Endocrinology and Metabolism|February 11, 2026
Will Selective Androgen Receptor Modulators Ever Reach The Clinic?Jenny Pena Dias, Adrian S Dobs
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|September 14, 2002
Streamlining the clinical research enterpriseBernard A Schwetz, Adrian S Dobs
Drugs|August 8, 2012
Topical testosterone supplementation for the treatment of male hypogonadismKatrina A Abadilla, Adrian S Dobs
Current Opinion in Endocrinology, Diabetes, and Obesity|October 18, 2007
Androgen deficiency, diabetes, and the metabolic syndrome in menRita R Kalyani, Adrian S Dobs
Expert Opinion on Pharmacotherapy|August 10, 2005
Nebido: a long-acting injectable testosterone for the treatment of male hypogonadismLindsey Harle, Shehzad Basaria, Adrian S Dobs
Pageof 12